Recurring glioblastoma patients participating in DelMar Pharmaceuticals' Phase 2 trial of VAL-083 recently began receiving the medicine.
The first person to receive the medicine was at the University of Texas' MD Anderson Cancer Center. VAL-083 is being tested for how well it can treat MGMT-unmethylated glioblastoma.
Patients receive 40 milligrams per square meter of body surface area of VAL-083 on the first, second and third days of three-week treatment cycle for up to 12 cycles. VAL-083 is being tested to see how well it works compared to other treatments previously used for glioblastoma multiforme.
In addition, the trial will help researchers learn how safe VAL-083 is and how well th3 48 participants of the trial tolerate it. Those who are being tested have growths that have come back after surgery and have had chemotherapy and radiation treatment that used temozolomide.